Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.

OBJECTIVES

Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability.

MATERIALS AND METHODS

We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib.

RESULTS AND CONCLUSION

Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it.